SYSCLAD

Systems prediction of Chronic Lung Allograft Dysfunction

Coordinatore	HOSPICES CANTONAUX CHUV    more  Organization address address: Rue du Bugnon 21 city: LAUSANNE postcode: 1005 contact info Titolo: Ms. Nome: Thuy Cognome: Oetli Email: send email Telefono: +41 2 13140303 Fax: +41 2 13144230
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	3˙932˙547 €
EC contributo	2˙999˙152 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2014-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	HOSPICES CANTONAUX CHUV  Organization address address: Rue du Bugnon 21 city: LAUSANNE postcode: 1005 contact info Titolo: Ms. Nome: Thuy Cognome: Oetli Email: send email Telefono: +41 2 13140303 Fax: +41 2 13144230	CH (LAUSANNE)	coordinator	454˙400.50
2	CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES  Organization address address: Allee de l'Ile Gloriette 5 city: NANTES postcode: 44093 contact info Titolo: Ms. Nome: Karine Cognome: Botturi-Cavaillès Email: send email Telefono: +33 2 28080126 Fax: +33 2 28080130	FR (NANTES)	participant	848˙700.00
3	UNIVERSITE JOSEPH FOURIER GRENOBLE 1  Organization address address: "Avenue Centrale, Domaine Universitaire 621" city: GRENOBLE postcode: 38041 contact info Titolo: Mr. Nome: Yann Cognome: Leroux Email: send email Telefono: +33 4 76514488 Fax: +33 4 76514313	FR (GRENOBLE)	participant	522˙200.00
4	GATC BIOTECH AG  Organization address address: JAKOB STADLER PLATZ 7 city: KONSTANZ postcode: 78467 contact info Titolo: Dr. Nome: Janet Cognome: Kenklies Email: send email Telefono: +49 7531 8160751 Fax: +49 7531 816081	DE (KONSTANZ)	participant	416˙616.00
5	NOVADISCOVERY SAS  Organization address address: AVENUE ROCKEFELLER 60 city: LYON postcode: 69008 contact info Titolo: Mr. Nome: François-Henri Cognome: Boissel Email: send email Telefono: 33675483181	FR (LYON)	participant	346˙970.00
6	BIOMAX INFORMATICS AG  Organization address address: ROBERT KOCH STRASSE 2 city: PLANEGG postcode: 82152 contact info Titolo: Dr. Nome: Dieter Cognome: Maier Email: send email Telefono: 4989900000000	DE (PLANEGG)	participant	243˙765.75
7	FINOVATIS  Organization address address: COURS LAFAYETTE 68 city: LYON postcode: 69003 contact info Titolo: Dr. Nome: David Cognome: Koubi Email: send email Telefono: 33478547940	FR (LYON)	participant	101˙000.00
8	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Mr. Nome: Andreas Cognome: Ledergerber Email: send email Telefono: +41 44 634 53 58	CH (ZURICH)	participant	37˙500.00
9	HLA ET MEDECINE  Organization address address: Avenue Claude Vellefaux 1 city: Paris postcode: 75010 contact info Titolo: Dr. Nome: Charles Cognome: Auffray Email: send email Telefono: 33698220449 Fax: 33437287401	FR (Paris)	participant	27˙999.75

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunction (CLAD) (i.e. “Bronchiolitis obliterans syndrome” (BOS) and “Restrictive Allograft Syndrome” (RAS)) represents a major health risk for LT recipients, requiring the use of heavy treatments and possible retransplantation. Observed in almost 50% of patients after 5 years post LT, it is currently impossible to predict the appearance of CLAD before the onset of first symptoms. This project aims to develop the SysCLAD model which will allow to predict, within the 1st year post LT, the recipients at risk of developing CLAD by 3 years post LT. Building upon available data from the cohort of lung transplantation (COLT, recruited since mid-2009), this project will integrate new LT recipients to form the European cohort of lung transplantation (ECOLT). The SysCLAD prediction tool will be based on a mathematical model developed through a system biology approach integrating both clinical and biological data collected from a total of 400 LT recipients. The model will be validated on the first 200 LT recipients (3 years follow-up at project start) and refined using the new set of 200 LT data with 3 years follow-up by 2014. The aim is to identify and validate the signature of CLAD both at the clinical and molecular levels to allow for an early recognition and specific interventions in patients at risk of CLAD. The implementation of the model is expected to significantly improve the cost-effectiveness of post-LT treatments, limit the risk of graft rejection in LT recipients and, ultimately lead to an improved quality of life and a prolonged life expectancy of patients following LT. Finally, the SysCLAD model holds further great promises in the context of other chronic bronchial inflammatory diseases of major incidence such as severe asthma and Chronic Obstructive Pulmonary Disease (COPD) to predict decline in lung function.'

Introduzione (Teaser)

European scientists developed a novel clinical mathematical tool capable of interpreting a particular molecular signature and predicting the outcome of lung transplantation (LT).